(19)
(11) EP 4 479 043 A1

(12)

(43) Date of publication:
25.12.2024 Bulletin 2024/52

(21) Application number: 23756861.3

(22) Date of filing: 16.02.2023
(51) International Patent Classification (IPC): 
A61K 31/40(2006.01)
A61K 31/395(2006.01)
A61K 31/33(2006.01)
A61K 31/351(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/40; A61K 45/06; A61K 31/7068; A61K 31/337; A61K 31/506; A61K 31/4184; A61K 31/495
 
C-Sets:
  1. A61K 31/495, A61K 2300/00;
  2. A61K 31/7068, A61K 2300/00;
  3. A61K 31/337, A61K 2300/00;
  4. A61K 31/506, A61K 2300/00;
  5. A61K 31/4184, A61K 2300/00;

(86) International application number:
PCT/US2023/013180
(87) International publication number:
WO 2023/158715 (24.08.2023 Gazette 2023/34)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 16.02.2022 US 202263268111 P

(71) Applicant: Immunomet Therapeutics Inc.
Houston, TX 77021 (US)

(72) Inventor:
  • WELSCH, Dean
    Houston, TX 77021 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) OXPHOS INHIBITORS FOR USE IN TREATING CANCER